Pelthos Therapeutics Reports Q3 2026 Loss of $(2.04) Per Share on Revenue of $15. ...
Product revenue more than doubles year over year, though quarterly net product sales slip slightly and GAAP EPS of $(2.04) trails the $(3.07) analyst estimate Related Stocks: PTHS ,